Toxicological Research

Korean Society of Toxicology & Korea Environmental Mutagen Society (한국독성학회)
권호 표지
DOI QR코드

DOI QR Code

HEBP2 affects sensitivity to cisplatin and BCNU but not to paclitaxel in MDA-MB-231 breast cancer cells

  • Hye Rim Kim (Department of Pharmacology, Sungkyunkwan University School of Medicine) ;
  • Jin-Kyung Hong (Department of Pharmacology, Sungkyunkwan University School of Medicine) ;
  • Yongsub Kim (Department of Cell and Genetic Engineering, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Jeong-Yun Choi (Department of Pharmacology, Sungkyunkwan University School of Medicine)
  • Received : 2024.04.22
  • Accepted : 2024.05.22
  • Published : 2024.10.15
⟨ Previous Next ⟩

Abstract

Breast cancer has the highest incidence of all cancer types in women. Triple-negative breast cancer (TNBC) accounts for 15% of all breast cancer cases and is the most aggressive type, with a poor prognosis and limited treatment. Treatment failure in patients is largely due to resistance to chemotherapy. In this study, we aimed to identify the novel factors contributing to chemoresistance in TNBC using cisplatin and 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU). We found that transactivation of the heme-binding protein 2 (HEBP2) gene was common in surviving colonies of cells after exposure to two types of chemotherapeutic agents, namely cisplatin and BCNU, from genome-scale transcriptional activation library screening in the TNBC cell line MDA-MB-231. Analysis of a public database (Proteogenomic Landscape of Breast Cancer, CPTAC) indicated that HEBP2 mRNA expression was elevated in TNBC tissues compared to that in non-TNBC tissues. HEBP2 facilitates necrotic cell death under oxidative stress; however, it is not yet known whether HEBP2 affects cancer cell survival following chemotherapy. Therefore, we investigated the effects of HEBP2 expression on the sensitivity to cisplatin and BCNU in MDA-MB-231 cells. Overexpression of HEBP2 significantly enhanced the viability of MDA-MB-231 cells in response to cisplatin and BCNU, but not methyl methanesulfonate (MMS) and paclitaxel. In contrast, CRISPR/Cas9-mediated HEBP2-knockout greatly reduced cell viability in response to cisplatin and BCNU, but not to MMS and paclitaxel, in MDA-MB-231 cells. Moreover, the exogenous introduction of HEBP2 restored the resistance of HEBP2-deficient cells to cisplatin and BCNU to wild-type levels. These findings suggest that HEBP2 may play a significant role in resistance to cisplatin and BCNU, which induce intrastrand and interstrand DNA crosslinks, but not to monoalkylating or microtubule-stabilizing agents in TNBC cells. The possibility exists that HEBP2 serves as a biomarker for predicting response or a therapeutic target for overcoming resistance to platinum-based and alkylating anticancer agents in TNBC.

Keywords

Acknowledgement

This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korean government (MIST) (NRF-2019R1A2C1008984).

References

  1. World Health Organization (2020) Latest global cancer data: cancer burden rises to 19.3 million new cases and 10.0 million cancer deaths in 2020. https://www.iarc.who.int/fr/news-events/latest-global-cancer-data-cancer-burden-rises-to-19-3-million-new-cases-and-10-0-million-cancer-deaths-in-2020. Accessed 1 Apr 2024 
  2. Blasiak J (2017) DNA-damaging anticancer drugs - a perspective for DNA repair- oriented therapy. Curr Med Chem 24:1488-1503. https://doi.org/10.2174/0929867324666170124145557 
  3. Bianchini G, Balko JM, Mayer IA et al (2016) Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol 13:674-690. https://doi.org/10.1038/nrclinonc.2016.66 
  4. Foulkes WD, Smith IE, Reis-Filho JS (2010) Triple-negative breast cancer. N Engl J Med 363:1938-1948. https://doi.org/10.1056/NEJMra1001389 
  5. Pareja F, Geyer FC, Marchio C et al (2016) Triple-negative breast cancer: the importance of molecular and histologic subtyping, and recognition of low-grade variants. NPJ Breast Cancer 2:16036. https://doi.org/10.1038/npjbcancer.2016.36 
  6. Yin L, Duan JJ, Bian XW et al (2020) Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res 22:61. https://doi.org/10.1186/s13058-020-01296-5 
  7. Mandapati A, Lukong KE (2023) Triple negative breast cancer: approved treatment options and their mechanisms of action. J Cancer Res Clin Oncol 149:3701-3719. https://doi.org/10.1007/s00432-022-04189-6 
  8. Ismail-Khan R, Bui MM (2010) A review of triple-negative breast cancer. Cancer Control 17:173-176. https://doi.org/10.1177/107327481001700305 
  9. Kumar P, Aggarwal R (2016) An overview of triple-negative breast cancer. Arch Gynecol Obstet 293:247-269. https://doi.org/10.1007/s00404-015-3859-y 
  10. Nedeljkovic M, Damjanovic A (2019) Mechanisms of chemotherapy resistance in triple-negative breast cancer-how we can rise to the challenge. Cells 8:957. https://doi.org/10.3390/cells8090957 
  11. Jamieson ER, Lippard SJ (1999) Structure, recognition, and processing of cisplatin-DNA adducts. Chem Rev 99:2467-2498. https://doi.org/10.1021/cr980421n 
  12. Wiencke JK, Wiemels J (1995) Genotoxicity of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU). Mutat Res 339:91-119. https://doi.org/10.1016/0165-1110(95)90005-5 
  13. Szigeti A, Hocsak E, Rapolti E et al (2010) Facilitation of mitochondrial outer and inner membrane permeabilization and cell death in oxidative stress by a novel Bcl-2 homology 3 domain protein. J Biol Chem 285:2140-2151. https://doi.org/10.1074/jbc.M109.015222 
  14. Konermann S, Brigham MD, Trevino AE et al (2015) Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex. Nature 517:583-588. https://doi.org/10.1038/nature14136 
  15. Krug K, Jaehnig EJ, Satpathy S et al (2020) Proteogenomic landscape of breast cancer tumorigenesis and targeted therapy. Cell 183:1436-1456. https://doi.org/10.1016/j.cell.2020.10.036 
  16. Gao J, Aksoy BA, Dogrusoz U et al (2013) Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 6:pl1. https://doi.org/10.1126/scisignal.2004088 
  17. Chandrashekar DS, Karthikeyan SK, Korla PK et al (2022) UALCAN: An update to the integrated cancer data analysis platform. Neoplasia 25:18-27. https://doi.org/10.1016/j.neo.2022.01.001 
  18. Shalem O, Sanjana NE, Hartenian E et al (2014) Genome-scale CRISPR-Cas9 knockout screening in human cells. Science 343:84-87. https://doi.org/10.1126/science.1247005 
  19. Freire F, Romao MJ, Macedo AL et al (2009) Preliminary structural characterization of human SOUL, a haem-binding protein. Acta Crystallogr Sect F Struct Biol Cryst Commun 65:723-726. https://doi.org/10.1107/S174430910902291X 
  20. Taketani S, Adachi Y, Kohno H et al (1998) Molecular characterization of a newly identified heme-binding protein induced during differentiation of urine erythroleukemia cells. J Biol Chem 273:31388-31394. https://doi.org/10.1074/jbc.273.47.31388 
  21. Qin J, Yang Y, Gao S et al (2017) Deregulated ALG-2/HEBP2 axis alters microtubule dynamics and mitotic spindle behavior to stimulate cancer development. J Cell Physiol 232:3067-3076. https://doi.org/10.1002/jcp.25754 
  22. Farkas R, Pozsgai E, Bellyei S et al (2011) Correlation between tumor-associated proteins and response to neoadjuvant treatment in patients with advanced squamous-cell esophageal cancer. Anticancer Res 31:1769-1775 
  23. Zoltan L, Farkas R, Schally AV et al (2019) Possible predictive markers of response to therapy in esophageal squamous cell cancer. Pathol Oncol Res 25:279-288. https://doi.org/10.1007/s12253-017-0342-z 
  24. Kohn KW (1977) Interstrand cross-linking of DNA by 1,3-bis(2-chloroethyl)-1-nitrosourea and other 1-(2-haloethyl)-1-nitrosoureas. Cancer Res 37:1450-1454 
  25. Malinge JM, Giraud-Panis MJ, Leng M (1999) Interstrand crosslinks of cisplatin induce striking distortions in DNA. J Inorg Biochem 77:23-29. https://doi.org/10.1016/s0162-0134(99)00148-8 
  26. Ovejero S, Soulet C, Moriel-Carretero M (2021) The alkylating agent methyl methanesulfonate triggers lipid alterations at the inner nuclear membrane that are independent from its DNA-damaging ability. Int J Mol Sci 22:7461. https://doi.org/10.3390/ijms22147461 
  27. Singla AK, Garg A, Aggarwal D (2002) Paclitaxel and its formulations. Int J Pharm 235:179-192. https://doi.org/10.1016/s0378-5173(01)00986-3 
  28. Fu R, Zhao B, Chen M et al (2023) Moving beyond cisplatin resistance: mechanisms, challenges, and prospects for overcoming recurrence in clinical cancer therapy. Med Oncol 41:9. https://doi.org/10.1007/s12032-023-02237-w 
  29. Xiao Y, Lin FT, Lin WC (2021) ACTL6A promotes repair of cisplatin-induced DNA damage, a new mechanism of platinum resistance in cancer. Proc Natl Acad Sci U S A 118:e2015808118. https://doi.org/10.1073/pnas.2015808118 
  30. Marullo R, Werner E, Degtyareva N et al (2013) Cisplatin induces a mitochondrial-ROS response that contributes to cytotoxicity depending on mitochondrial redox status and bioenergetic functions. PLoS One 8:e81162. https://doi.org/10.1371/journal.pone.0081162 
  31. Frischer H, Ahmad T (1977) Severe generalized glutathione reductase deficiency after antitumor chemotherapy with BCNU" [1,3-bis(chloroethyl)-1-nitrosourea]. J Lab Clin Med 89:1080-1091 
  32. Rowe LA, Degtyareva N, Doetsch PW (2008) DNA damage-induced reactive oxygen species (ROS) stress response in Saccharomyces cerevisiae. Free Radic Biol Med 45:1167-1177. https://doi.org/10.1016/j.freeradbiomed.2008.07.018 
  33. Goodfellow BJ, Freire F, Carvalho AL et al (2021) The SOUL family of heme-binding proteins: Structure and function 15 years later. Coord Chem Rev 448:214189. https://doi.org/10.1016/j.ccr.2021.214189